BIOSYENT INC (RX.CA) Stock Fundamental Analysis
TSX-V:RX - TSX Venture Exchange - CA0906901081 - Common Stock - Currency: CAD
RX gets a fundamental rating of 8 out of 10. The analysis compared the fundamentals against 32 industry peers in the Pharmaceuticals industry. RX gets an excellent profitability rating and is at the same time showing great financial health properties. RX scores decently on growth, while it is valued quite cheap. This could make an interesting combination. These ratings would make RX suitable for value and quality investing!
1. Profitability
1.1 Basic Checks
RX had positive earnings in the past year.
In the past year RX had a positive cash flow from operations.
Each year in the past 5 years RX has been profitable.
In the past 5 years RX always reported a positive cash flow from operatings.
1.2 Ratios
With an excellent Return On Assets value of 17.58%, RX belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
RX has a better Return On Equity (20.77%) than 100.00% of its industry peers.
With an excellent Return On Invested Capital value of 18.91%, RX belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
RX had an Average Return On Invested Capital over the past 3 years of 16.58%. This is significantly above the industry average of 7.70%.
The last Return On Invested Capital (18.91%) for RX is above the 3 year average (16.58%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.58% | ||
| ROE | 20.77% | ||
| ROIC | 18.91% |
ROA(3y)15.54%
ROA(5y)14.96%
ROE(3y)18.57%
ROE(5y)17.96%
ROIC(3y)16.58%
ROIC(5y)16.4%
1.3 Margins
RX has a better Profit Margin (20.75%) than 93.75% of its industry peers.
In the last couple of years the Profit Margin of RX has remained more or less at the same level.
RX has a Operating Margin of 25.88%. This is amongst the best in the industry. RX outperforms 96.88% of its industry peers.
RX's Operating Margin has declined in the last couple of years.
The Gross Margin of RX (79.52%) is better than 96.88% of its industry peers.
RX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 25.88% | ||
| PM (TTM) | 20.75% | ||
| GM | 79.52% |
OM growth 3Y-3.53%
OM growth 5Y-2.73%
PM growth 3Y-1.85%
PM growth 5Y0.35%
GM growth 3Y0.17%
GM growth 5Y0.46%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so RX is creating value.
The number of shares outstanding for RX has been reduced compared to 1 year ago.
RX has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, RX has an improved debt to assets ratio.
2.2 Solvency
RX has an Altman-Z score of 14.97. This indicates that RX is financially healthy and has little risk of bankruptcy at the moment.
RX has a better Altman-Z score (14.97) than 100.00% of its industry peers.
The Debt to FCF ratio of RX is 0.12, which is an excellent value as it means it would take RX, only 0.12 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 0.12, RX belongs to the best of the industry, outperforming 96.88% of the companies in the same industry.
RX has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
RX has a better Debt to Equity ratio (0.02) than 78.13% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.12 | ||
| Altman-Z | 14.97 |
ROIC/WACC2.25
WACC8.42%
2.3 Liquidity
RX has a Current Ratio of 4.53. This indicates that RX is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of RX (4.53) is better than 96.88% of its industry peers.
A Quick Ratio of 3.54 indicates that RX has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 3.54, RX belongs to the top of the industry, outperforming 96.88% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.53 | ||
| Quick Ratio | 3.54 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 15.83% over the past year.
RX shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 15.02% yearly.
RX shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 10.89%.
RX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.33% yearly.
EPS 1Y (TTM)15.83%
EPS 3Y8.39%
EPS 5Y15.02%
EPS Q2Q%13.99%
Revenue 1Y (TTM)10.89%
Revenue growth 3Y6.97%
Revenue growth 5Y10.33%
Sales Q2Q%6.32%
3.2 Future
RX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.39% yearly.
RX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.14% yearly.
EPS Next Y32.4%
EPS Next 2Y19.94%
EPS Next 3Y15.39%
EPS Next 5YN/A
Revenue Next Year17.23%
Revenue Next 2Y12.37%
Revenue Next 3Y10.14%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 17.74, the valuation of RX can be described as rather expensive.
Compared to the rest of the industry, the Price/Earnings ratio of RX indicates a rather cheap valuation: RX is cheaper than 81.25% of the companies listed in the same industry.
RX is valuated rather cheaply when we compare the Price/Earnings ratio to 24.21, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 13.31, which indicates a correct valuation of RX.
RX's Price/Forward Earnings ratio is rather cheap when compared to the industry. RX is cheaper than 90.63% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of RX to the average of the S&P500 Index (20.44), we can say RX is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.74 | ||
| Fwd PE | 13.31 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, RX is valued a bit cheaper than the industry average as 71.88% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, RX is valued a bit cheaper than the industry average as 68.75% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.63 | ||
| EV/EBITDA | 10.87 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
RX has an outstanding profitability rating, which may justify a higher PE ratio.
RX's earnings are expected to grow with 15.39% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.55
PEG (5Y)1.18
EPS Next 2Y19.94%
EPS Next 3Y15.39%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 1.71%, RX has a reasonable but not impressive dividend return.
Compared to an average industry Dividend Yield of 3.14, RX pays a better dividend. On top of this RX pays more dividend than 96.88% of the companies listed in the same industry.
Compared to the average S&P500 Dividend Yield of 2.44, RX is paying slightly less dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.71% |
5.2 History
RX has been paying a dividend for less than 5 years, so it still needs to build a track record.
Dividend Growth(5Y)N/A
Div Incr Years2
Div Non Decr Years2
5.3 Sustainability
28.61% of the earnings are spent on dividend by RX. This is a low number and sustainable payout ratio.
DP28.61%
EPS Next 2Y19.94%
EPS Next 3Y15.39%
TSX-V:RX (5/8/2025, 7:00:00 PM)
11
+0.1 (+0.92%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners3.18%
Inst Owner ChangeN/A
Ins Owners17.25%
Ins Owner ChangeN/A
Market Cap126.17M
Analysts82.86
Price Target11.99 (9%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.71% |
Yearly Dividend0.18
Dividend Growth(5Y)N/A
DP28.61%
Div Incr Years2
Div Non Decr Years2
Ex-Date
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)15.78%
Min EPS beat(2)-8.5%
Max EPS beat(2)40.06%
EPS beat(4)3
Avg EPS beat(4)36.69%
Min EPS beat(4)-8.5%
Max EPS beat(4)83.82%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.7%
Min Revenue beat(2)-5.23%
Max Revenue beat(2)1.83%
Revenue beat(4)2
Avg Revenue beat(4)-0.44%
Min Revenue beat(4)-5.23%
Max Revenue beat(4)5.66%
Revenue beat(8)4
Avg Revenue beat(8)-1.91%
Revenue beat(12)5
Avg Revenue beat(12)-2.4%
Revenue beat(16)8
Avg Revenue beat(16)0.84%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)1.25%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.72%
Revenue NY rev (3m)-0.72%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.74 | ||
| Fwd PE | 13.31 | ||
| P/S | 3.6 | ||
| P/FCF | 14.63 | ||
| P/OCF | 14.56 | ||
| P/B | 3.6 | ||
| P/tB | 4.21 | ||
| EV/EBITDA | 10.87 |
EPS(TTM)0.62
EY5.64%
EPS(NY)0.83
Fwd EY7.51%
FCF(TTM)0.75
FCFY6.83%
OCF(TTM)0.76
OCFY6.87%
SpS3.05
BVpS3.05
TBVpS2.61
PEG (NY)0.55
PEG (5Y)1.18
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.58% | ||
| ROE | 20.77% | ||
| ROCE | 25.21% | ||
| ROIC | 18.91% | ||
| ROICexc | 33.97% | ||
| ROICexgc | 45.41% | ||
| OM | 25.88% | ||
| PM (TTM) | 20.75% | ||
| GM | 79.52% | ||
| FCFM | 24.61% |
ROA(3y)15.54%
ROA(5y)14.96%
ROE(3y)18.57%
ROE(5y)17.96%
ROIC(3y)16.58%
ROIC(5y)16.4%
ROICexc(3y)59.42%
ROICexc(5y)88.26%
ROICexgc(3y)72.91%
ROICexgc(5y)116.75%
ROCE(3y)22.1%
ROCE(5y)21.86%
ROICexcg growth 3Y-33.84%
ROICexcg growth 5Y-15.21%
ROICexc growth 3Y-35.8%
ROICexc growth 5Y-16.72%
OM growth 3Y-3.53%
OM growth 5Y-2.73%
PM growth 3Y-1.85%
PM growth 5Y0.35%
GM growth 3Y0.17%
GM growth 5Y0.46%
F-Score7
Asset Turnover0.85
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.12 | ||
| Debt/EBITDA | 0.09 | ||
| Cap/Depr | 7.17% | ||
| Cap/Sales | 0.12% | ||
| Interest Coverage | 153.11 | ||
| Cash Conversion | 89.74% | ||
| Profit Quality | 118.58% | ||
| Current Ratio | 4.53 | ||
| Quick Ratio | 3.54 | ||
| Altman-Z | 14.97 |
F-Score7
WACC8.42%
ROIC/WACC2.25
Cap/Depr(3y)10.2%
Cap/Depr(5y)10.36%
Cap/Sales(3y)0.16%
Cap/Sales(5y)0.17%
Profit Quality(3y)95.24%
Profit Quality(5y)108.02%
High Growth Momentum
Growth
EPS 1Y (TTM)15.83%
EPS 3Y8.39%
EPS 5Y15.02%
EPS Q2Q%13.99%
EPS Next Y32.4%
EPS Next 2Y19.94%
EPS Next 3Y15.39%
EPS Next 5YN/A
Revenue 1Y (TTM)10.89%
Revenue growth 3Y6.97%
Revenue growth 5Y10.33%
Sales Q2Q%6.32%
Revenue Next Year17.23%
Revenue Next 2Y12.37%
Revenue Next 3Y10.14%
Revenue Next 5YN/A
EBIT growth 1Y20.31%
EBIT growth 3Y3.2%
EBIT growth 5Y7.32%
EBIT Next Year41.79%
EBIT Next 3Y15.52%
EBIT Next 5YN/A
FCF growth 1Y72.58%
FCF growth 3Y23.38%
FCF growth 5Y17.21%
OCF growth 1Y71.38%
OCF growth 3Y22.83%
OCF growth 5Y14.5%